The Value of Serum Cystatin C (Cyst-c) Level in Detecting Early Renal Damage in Hypertension or Coronary Arteriosclerotic Heart Disease

Objective To estimate the value of serum Cystatin C (Cyst-c) level in detecting early arteriosclerotic renal damage in hypertension or coronary arteriosclerotic heart disease (CHD) and the treatment effect of Cilazapril. Methods Serum Cyst-c and creatinine (Cr) levels were determined in 201 hypertension or CHD patients with arteriosclerosis and compared with those in control group. Among them, 50 early renal damage patients with grade I hypertension who had higher serum Cyst-c but normal serum Cr level were treated with cilazapril 2.5-3.75mg/d for 3 months. Serum Cyst-c was measured before and after Cilazapril treatment. Results Among 201 arteriosclerosis patients, there were 92 cases with early renal damage (45.77%), 16 cases with renal failure (7.96%), 93 cases with normal renal function (46.26%). Serum Cyst-c level in the early renal damage group was significantly higher than in the control group (2.18±0.51mg/L vs 1.14±0.40mg/L, P0.001). Serum Cyst-c level in 50 patients with grade I hypertension decreased from 2.24±0.51mg/L to 1.86±0.53mg/L after Cilazapril treatment (P0.001). There was no difference in serum Cr level between the early lenal damage group and control group (81.33±14.12μmol/L vs 79.86±12.41μmol/L, P0.05). Conclusions Early arteriosclerotic renal damage is 45.77% in hypertension or CHD patients. serum Cyst-c level is a more sensitive indicator of detecting early renal damage than serum Cr level. Cilazapril is an effective treatment for early renal damage in arteriosclerotic disease.